ID26086A - Ligan-ligan reseptor 5ht1 azabisiklik - Google Patents

Ligan-ligan reseptor 5ht1 azabisiklik

Info

Publication number
ID26086A
ID26086A IDW20002017A ID20002017A ID26086A ID 26086 A ID26086 A ID 26086A ID W20002017 A IDW20002017 A ID W20002017A ID 20002017 A ID20002017 A ID 20002017A ID 26086 A ID26086 A ID 26086A
Authority
ID
Indonesia
Prior art keywords
azhticiclic
ligans
receptor
receptor ligans
Prior art date
Application number
IDW20002017A
Other languages
English (en)
Indonesian (id)
Inventor
Gene Michael Bright
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID26086A publication Critical patent/ID26086A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
IDW20002017A 1998-04-09 1999-03-18 Ligan-ligan reseptor 5ht1 azabisiklik ID26086A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09

Publications (1)

Publication Number Publication Date
ID26086A true ID26086A (id) 2000-11-23

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002017A ID26086A (id) 1998-04-09 1999-03-18 Ligan-ligan reseptor 5ht1 azabisiklik

Country Status (41)

Country Link
US (2) US6525048B1 (xx)
EP (1) EP1070065B1 (xx)
JP (1) JP3496759B2 (xx)
KR (1) KR100378931B1 (xx)
CN (1) CN1117092C (xx)
AP (1) AP1175A (xx)
AR (1) AR015751A1 (xx)
AT (1) ATE248838T1 (xx)
AU (1) AU749254B2 (xx)
BG (1) BG104915A (xx)
BR (1) BR9909522A (xx)
CA (1) CA2327782A1 (xx)
CO (1) CO5080727A1 (xx)
CZ (1) CZ20003684A3 (xx)
DE (1) DE69910997T2 (xx)
DK (1) DK1070065T3 (xx)
DZ (1) DZ2756A1 (xx)
EA (1) EA003400B1 (xx)
ES (1) ES2204154T3 (xx)
HK (1) HK1035719A1 (xx)
HR (1) HRP20000653A2 (xx)
HU (1) HUP0102400A3 (xx)
ID (1) ID26086A (xx)
IL (1) IL138629A0 (xx)
IS (1) IS5641A (xx)
MA (1) MA26619A1 (xx)
MY (1) MY133390A (xx)
NO (1) NO20005004L (xx)
NZ (1) NZ507010A (xx)
OA (1) OA11496A (xx)
PA (1) PA8469101A1 (xx)
PE (1) PE20000413A1 (xx)
PL (1) PL343408A1 (xx)
PT (1) PT1070065E (xx)
SK (1) SK14782000A3 (xx)
TN (1) TNSN99056A1 (xx)
TR (1) TR200002932T2 (xx)
TW (1) TW555758B (xx)
WO (1) WO1999052907A1 (xx)
YU (1) YU59400A (xx)
ZA (1) ZA992596B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
ATE318135T1 (de) * 1999-09-03 2006-03-15 Apbi Holdings Llc Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
AU2004220327B2 (en) * 2003-03-12 2010-06-24 Pfizer Products Inc. Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
BRPI0512567A (pt) * 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical PREVENTIVE / REMEDY AGENTS FOR INCONTINENCE OF STRESS AND SELECETING METHOD THEREOF
US20070270430A1 (en) * 2004-09-10 2007-11-22 Pfzer Inc Methods of Treating Cognitive Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
EP0607163B1 (en) * 1991-09-25 1996-12-11 Pfizer Inc. NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
JP2753146B2 (ja) * 1992-06-16 1998-05-18 ファイザー・インコーポレーテッド ビス−アザー二環式抗不安薬の製法および中間体
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5731307A (en) * 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
HUP0102400A3 (en) 2002-10-28
MY133390A (en) 2007-11-30
CZ20003684A3 (cs) 2002-03-13
AU749254B2 (en) 2002-06-20
EA003400B1 (ru) 2003-04-24
DE69910997T2 (de) 2004-05-19
DK1070065T3 (da) 2003-11-24
AP9901502A0 (en) 1999-06-30
KR100378931B1 (ko) 2003-04-07
PT1070065E (pt) 2003-12-31
JP3496759B2 (ja) 2004-02-16
WO1999052907A1 (en) 1999-10-21
PL343408A1 (en) 2001-08-13
AU3268799A (en) 1999-11-01
BG104915A (en) 2001-07-31
TNSN99056A1 (fr) 2005-11-10
TW555758B (en) 2003-10-01
EP1070065A1 (en) 2001-01-24
IS5641A (is) 2000-09-26
BR9909522A (pt) 2000-12-19
SK14782000A3 (sk) 2002-06-04
EA200000910A1 (ru) 2001-04-23
JP2002511469A (ja) 2002-04-16
US20030181458A1 (en) 2003-09-25
HK1035719A1 (en) 2001-12-07
YU59400A (sh) 2003-10-31
PE20000413A1 (es) 2000-05-25
EP1070065B1 (en) 2003-09-03
ATE248838T1 (de) 2003-09-15
MA26619A1 (fr) 2004-12-20
AR015751A1 (es) 2001-05-16
PA8469101A1 (es) 2000-09-29
CN1117092C (zh) 2003-08-06
NO20005004D0 (no) 2000-10-04
ES2204154T3 (es) 2004-04-16
CO5080727A1 (es) 2001-09-25
US6887905B2 (en) 2005-05-03
HUP0102400A2 (hu) 2001-11-28
NO20005004L (no) 2000-11-27
OA11496A (en) 2004-05-14
AP1175A (en) 2003-06-04
CA2327782A1 (en) 1999-10-21
DE69910997D1 (de) 2003-10-09
NZ507010A (en) 2003-05-30
US6525048B1 (en) 2003-02-25
KR20010042527A (ko) 2001-05-25
CN1305477A (zh) 2001-07-25
DZ2756A1 (fr) 2003-09-15
TR200002932T2 (tr) 2001-01-22
HRP20000653A2 (en) 2001-04-30
IL138629A0 (en) 2001-10-31
ZA992596B (en) 2000-10-08

Similar Documents

Publication Publication Date Title
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
DE59910140D1 (de) Gleitschalungsfertiger
LTC1124961I2 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69900007D1 (de) Paroxetinmethansulfonat
NO20011745L (no) Forbindelser
ID23287A (id) Trisiklik tersubstitusi
ID23458A (id) Bentuk sediaan nefazodon
NO981305D0 (no) Utblåsningssikring
ID27004A (id) Senyawa-senyawa kalsilitik
NO20013997D0 (no) Reseptoranalyse
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
ID23219A (id) Trisiklik tersubstitusi
NO20006662D0 (no) Fluorfenylresin-forbindelser
NO990717D0 (no) Monitor-st°ttemekanisme
ID23196A (id) Gandaran untuk lampuflouresen
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
ATE303996T1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
DE59911610D1 (de) Substituierte benzoylcyclohexandione
DE69937563D1 (de) Neuer gaba-b rezeptor
NO20005325D0 (no) Bjelkelagskonstruksjon
DE59913690D1 (de) Baueinheit